Percheron Therapeutics Limited (ASX:PER)

Market Cap	11.96M
Revenue (ttm)	1.92M
Net Income (ttm)	-15.71M
Shares Out	1.09B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	922,016
Average Volume	1,564,631
Open	0.0100
Previous Close	0.0100
Day's Range	0.0100 - 0.0110
52-Week Range	0.0050 - 0.1400
Beta	0.99
RSI	60.03
Earnings Date	May 20, 2025

About Percheron Therapeutics

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company’s product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expressi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 8
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PER

Financial Performance

In 2024, Percheron Therapeutics's revenue was 2.97 million, an increase of 51.07% compared to the previous year's 1.96 million. Losses were -11.92 million, 4.74% more than in 2023.